Abstract
Epidemiological studies have recently shown that obesity, and abdominal obesity in particular, is an independent risk factor for the development of heart failure (HF). Higher cardiac oxidative stress is the early stage of heart dysfunction due to obesity, and it is the result of insulin resistance, altered fatty acid and glucose metabolism, and impaired mitochondrial biogenesis. Extense myocyte hypertrophy and myocardial fibrosis are early microscopic changes in patients with HF, whereas circumferential strain during the left ventricular (LV) systole, LV increase in both chamber size and wall thickness (LV hypertrophy), and LV dilatation are the early macroscopic and functional alterations in obese developing heart failure. LV hypertrophy leads to diastolic dysfunction and subendocardial ischemia in obesity, and pericardial fat has been shown to be significantly associated with LV diastolic dysfunction. Evolving abnormalities of diastolic dysfunction may include progressive hypertrophy and systolic dysfunction, and various degrees of eccentric and/or concentric LV hypertrophy may be present with time. Once HF is established, overweight and obese have a better prognosis than do their lean counterparts with the same level of cardiovascular disease, and this phenomenon is called “obesity paradox”. It is mainly due to lower muscle protein degradation, brain natriuretic peptide circulating levels and cardio-respiratory fitness than normal weight patients with HF.
Keywords: Body fat distributor, heart failure, obesity, obesity paradox.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Obesity and Heart Failure
Volume: 13 Issue: 1
Author(s): Giovanni De Pergola, Adele Nardecchia, Vito Angelo Giagulli, Vincenzo Triggiani, Edoardo Guastamacchia, Manuela Castiglione Minischetti and Franco Silvestris
Affiliation:
Keywords: Body fat distributor, heart failure, obesity, obesity paradox.
Abstract: Epidemiological studies have recently shown that obesity, and abdominal obesity in particular, is an independent risk factor for the development of heart failure (HF). Higher cardiac oxidative stress is the early stage of heart dysfunction due to obesity, and it is the result of insulin resistance, altered fatty acid and glucose metabolism, and impaired mitochondrial biogenesis. Extense myocyte hypertrophy and myocardial fibrosis are early microscopic changes in patients with HF, whereas circumferential strain during the left ventricular (LV) systole, LV increase in both chamber size and wall thickness (LV hypertrophy), and LV dilatation are the early macroscopic and functional alterations in obese developing heart failure. LV hypertrophy leads to diastolic dysfunction and subendocardial ischemia in obesity, and pericardial fat has been shown to be significantly associated with LV diastolic dysfunction. Evolving abnormalities of diastolic dysfunction may include progressive hypertrophy and systolic dysfunction, and various degrees of eccentric and/or concentric LV hypertrophy may be present with time. Once HF is established, overweight and obese have a better prognosis than do their lean counterparts with the same level of cardiovascular disease, and this phenomenon is called “obesity paradox”. It is mainly due to lower muscle protein degradation, brain natriuretic peptide circulating levels and cardio-respiratory fitness than normal weight patients with HF.
Export Options
About this article
Cite this article as:
Pergola De Giovanni, Nardecchia Adele, Giagulli Angelo Vito, Triggiani Vincenzo, Guastamacchia Edoardo, Minischetti Castiglione Manuela and Silvestris Franco, Obesity and Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010007
DOI https://dx.doi.org/10.2174/1871530311313010007 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
Call for Papers in Thematic Issues
Association between Diabetes Mellitus and natural product complementary applications: State of the arts
Diabetes Mellitus (DM) represents a significant global health challenge, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The increasing prevalence of DM, alongside its associated complications, has prompted researchers and healthcare professionals to explore a variety of management strategies beyond conventional pharmacotherapy. Among these ...read more
Chronic inflammation and Disorders/Cancers
Chronic inflammation is fundamental cause of variety of disorders. Many lifestyle-related diseases including metabolic syndrome, obesity, impairment of immune responses, sepsis, mental illness, and other disorders are caused by chronic inflammation. Prevention of chronic inflammation is related to antiaging effects of our body. Proinflammatory cytokines such as TNF-α is associated ...read more
Immune defense of the blood-tissue barriers which are related to drugs, metabolic and hormones
We have already known that testis is an immune privilege area for the maintenance of spermatogenesis against to any pathogen from the interstitial area. With the BTB integrity there is a qualified selection for the mature sperm until the lumen migration which is sperm release progress. Spermiogenesis help for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Justification of Increasing the Blood Flow Velocity in the Arteries of the Thyroid Gland in Autoimmune Thyroiditis as a Reflection of Endothelial Changes Due to Inflammatory Status
Current Medical Imaging Innate Immunity and the Heart
Current Pharmaceutical Design Cyclophilin D-mediated Mitochondrial Permeability Transition Regulates Mitochondrial Function
Current Pharmaceutical Design Treatment of Acute Hypercalcemia
Medicinal Chemistry Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science New Oral Anticoagulation after Heart Valve Replacement
Cardiovascular & Hematological Disorders-Drug Targets New Assay for Old Markers-Plasma Beta Amyloid of Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Cardiovascular & Hematological Agents in Medicinal Chemistry Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry Endothelial Function Assessment in Complicated Hypertension
Current Pharmaceutical Design Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Gene Delivery System: A Developing Arena of Study for the New Era of Medicine
Recent Patents on DNA & Gene Sequences The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism The Relationship Between 24-Hour Indicators and Mortality in Patients with Exertional Heat Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease
Current Pharmaceutical Design Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?
Current Molecular Medicine